Xolair Pediatric (Ages 6-11) BLA Extension Must Overcome "Relatively Modest" Efficacy
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA briefing materials for Nov. 18 advisory committee meeting note reductions in asthma exacerbations but few clinically meaningful benefits on secondary efficacy measures.
You may also be interested in...
Novartis Pediatric Post-Market Plans For Xolair Fall Short Of FDA Request
A post-market program designed by Novartis to control Xolair (omalizumab) in the 6-11 pediatric population was not adequate to convince FDA or its Pulmonary-Allergy Drugs Advisory Committee to extend the indication for use in moderate to severe allergy/asthma patients below 12 years of age
Novartis Pediatric Post-Market Plans For Xolair Fall Short Of FDA Request
A post-market program designed by Novartis to control Xolair (omalizumab) in the 6-11 pediatric population was not adequate to convince FDA or its Pulmonary-Allergy Drugs Advisory Committee to extend the indication for use in moderate to severe allergy/asthma patients below 12 years of age
Xolair Pediatric Indication Is Too Broad, Clinical Effect Too Small For FDA Committee
Seven-seven split on first key vote on "clinically meaningful beneficial effect" of omalizumab in children above age six sends decision on BLA back to FDA - not a friendly venue for sponsors Genentech and Novartis. The three FDA staffs involved in the BLA review (pediatric, pulmonary and drug safety) are united in opposition to current application.